Kohl's Corporation vs Sana Biotechnology Inc — how do they compare? Kohl's Corporation trades at $19.24 (market cap $2.10B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Kohl's Corporation is the larger of the two by market cap, and Kohl's Corporation pays a 2.7% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KSS | SANA | |
|---|---|---|
Market Cap | $2.10B | $1.13B |
Sector | Consumer Cyclical | Health |
52-Week High | $24.71 | $5.92 |
52-Week Low | $11.72 | $2.68 |
Enterprise Value | $8.20B | $1.05B |
Dividend Yield | 2.7% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Trailing returns across standard periods
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →